MaaT Pharma, SA
About MaaT Pharma, SA
MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CEO: Herve´ Affagard
Co-Founder and Non Executive President of the Board: Dr Pierre Belichard
Co-Founder: Mr. Joël Doré
Co-Founder: Mr. Pierre Rimbaud
CAREER:
Please click here for Auspherix's job opportunities.
PIPELINE:
Please click here for MaaT Pharma's pipeline.
72 articles with MaaT Pharma, SA
-
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
1/27/2023
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by Kepler Cheuvreux.
-
MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023
1/24/2023
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, provides a corporate update highlighting the progress, adjustments to clinical programs and key development milestones expected in 2023.
-
MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
12/11/2022
MaaT Pharma presented detailed results from the completed Phase 1b CIMON trial with MaaT033 at the Annual Society of Hematology Annual Meeting in New Orleans, U.S.
-
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
12/10/2022
MaaT Pharma presented data from the continuing compassionate use program in France for MaaT013 at the Annual Society of Hematology Annual Meeting in New Orleans, U.S.
-
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
11/29/2022
MaaT Pharma announced that it will host an investor webcast on Monday, December 12th, 2022 at 12:00 pm EST / 6:00 pm CET to comment on clinical data scheduled to be presented at the 64th American Society of Hematology Annual Meeting and provide a corporate update for shareholders and the broader financial community.
-
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
11/8/2022
Regulatory News: MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.
-
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November 2022
11/7/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announced the company’s scientific and management team’s participation in several scientific and investor conferences in November.
-
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
11/3/2022
MaaT Pharma (EURONEXT: MAAT – the “Company”) announced today that extended results from its Early Access Program (EAP) of MaaT013 in patients with GI-aGvHD have been selected for oral presentation at the 64thAmerican Society of Hematology (ASH) Annual Meeting held from December 10-13, 2022, in New-Orleans, Louisiana, U.S.A.
-
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology
10/4/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announced the appointment of Nathalie Corvaïa, Ph.D., as Chief Scientific Officer.
-
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September 2022
9/8/2022
MaaT Pharma announced that Hervé Affagard, CEO and co-founder of MaaT Pharma, and Siân Crouzet, CFO of MaaT Pharma, will participate in three upcoming investor conferences.
-
Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.
-
MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.
-
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
7/28/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, reported its cash position as of June 30, 2022, and its revenues for the second quarter of 2022.
-
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
5/24/2022
MaaT Pharmam announced that it will host its first R&D Day for analysts and investors to be held virtually on Tuesday, June 7th, 2022 from 4:00 pm CEST to 6:00 pm CEST.
-
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
5/5/2022
Regulatory News: MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported its cash position as of March 31, 2022, and its revenues for the first quarter of 2022.
-
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
4/21/2022
MaaT Pharma announced on March 28th, 2022, the inclusion of the first patient in a pivotal Phase 3 clinical trial, potentially the last step of clinical development before marketing authorization, evaluating MaaT013 for the treatment of acute gastrointestinal Graft-versus-Host Disease, a serious complication following stem cell transplantation.
-
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview
4/14/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported full-year 2021 revenues and provided a business overview for 2022.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
3/28/2022
MaaT Pharma announced that the first patient has been dosed in its pivotal Phase 3 trial investigating MaaT013 in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement who are refractory to both steroids, the standard of care first-line treatment, and to ruxolitinib1 used as a second-line treatment.